Category Archives: Irbesartan

Irbesartan: CONCLUSIONS

At first glance, the ARBs appear to be a relatively homogeneous group of antihypertensive agents, interrupting the RAS at the receptor level. On the one hand, they appear to exhibit varying degrees of specificity for the AT1 receptor subtype. On … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(8)

Safety profile For most antihypertensive cheap drugs, it is possible to improve the therapeutic response by increasing the dose; however, such an increase can also be associated with a parallel rise in adverse event rates. Beyond a given dose, the … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(7)

Based on the results with irbesartan in the pilot trial with amlodipine, the fully recruited Irbesartan Diabetic Nephropathy Trial (IDNT) has been designed to assess the impact of irbesartan on overall mortality and the progression of renal disease in high … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(6)

Renoprotective properties A study comparing the hemodynamic effects of irbesartan and enalapril in hypertensive patients found that, whereas both agents resulted in renal vasodilation with no significant change in glomerular filtration rate, they differed significantly in their time course . … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(5)

More recently, irbesartan has been demonstrated to reduce QT dispersion, an attribute that may have implications for preventing sudden cardiac death in at-risk hypertensive patients . Data were analyzed from 104 patients in a 24-week trial of irbesartan (75 to … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(4)

Irbesartan has also shown potential in animal and human models of heart failure. Animal studies have found that irbe-sartan dose-dependently improved survival rates in models of postischemic congestive heart failure, and dose-dependently reduced myocardial hypertrophy (-16% and -27% versus controls … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(3)

Thromboxane A2 receptors: There appear to be differences among ARBs in terms of their potential to inhibit vascular thrombosis. For example, irbesartan, but not candesartan, inhibits prostaglandin-induced vasoconstriction in a dose-dependent manner . In a study by Brosnihan et al … Continue reading

Irbesartan: BEYOND BLOOD PRESSURE CONTROL(1)

Numerous trials have indicated the potential for irbesartan as a cardioprotective and renoprotective agent.

Irbesartan: CLINICAL IMPLICATIONS(2)

It is also important to note other features of these trials not listed in Table 2. For example, reductions in SeSBP were also significantly greater with irbesartan 300 mg compared with losartan 100 mg by 5.1 mmHg (-16.4 versus -11.3 … Continue reading

Irbesartan: CLINICAL IMPLICATIONS(1)

Comparative antihypertensive effects of ARBs Because losartan was the first approved ARB, it has become an important benchmark for within-class comparisons with respect to antihypertensive effect. As such, six trials have been conducted to date comparing the antihypertensive effects of … Continue reading